Stage-dependent prognostic value of programmed death ligand-1 expression in gastric cancer: Implications for personalized immunotherapy

doi:10.3748/wjg.118762

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 34

This Article

(5)

(0)

(35)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Opinion Review

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Sep 14, 2026; 32(34): 118762
Published online Sep 14, 2026. doi: 10.3748/wjg.118762

Stage-dependent prognostic value of programmed death ligand-1 expression in gastric cancer: Implications for personalized immunotherapy

Koji Takahashi

Koji Takahashi, Department of Gastroenterology, Eastern Chiba Medical Center, Togane 283-8686, Chiba, Japan

Koji Takahashi, Department of General Medical Science, Graduate School of Medicine, Chiba University, Chiba 260-8677, Japan

Author contributions: Takahashi K wrote the original draft.

Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.

Corresponding author: Koji Takahashi, MD, Department of Gastroenterology, Eastern Chiba Medical Center, 3-6-2, Okayamadai, Togane 283-8686, Chiba, Japan. koji517@gmail.com

Received: January 12, 2026
Revised: January 31, 2026
Accepted: March 10, 2026
Published online: September 14, 2026
Processing time: 221 Days and 11.7 Hours

Core Tip

Core Tip: This review reappraises programmed death ligand-1 expression in gastric cancer and gastroesophageal junction cancer as a dynamic reflection of the tumor microenvironment. We examine the stage-dependent prognostic shift of programmed death ligand-1 and immune phenotypes (inflamed, excluded, and desert). By integrating phase III trial data with molecular subtypes like Epstein-Barr virus and microsatellite instability, we highlight limitations of simplified scoring. We propose personalized immunotherapy, driven by spatial analysis and dynamic monitoring, to optimize outcomes across the complex biological landscape of gastric cancer.